BRST5:Fibroadenoma - Revision history

Richard.Glen at 01:25, 26 February 2026

2026-02-26T01:25:52Z

← Older revision		Revision as of 20:25, 25 February 2026
Line 230:		Line 230:
	==References==		==References==
	<br />		<br />
			<references />

	==Notes==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.
Line 238:		Line 240:
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases F]]		[[Category:Diseases F]]
	~~<references />~~

Bailey.Glen at 17:46, 3 July 2025

2025-07-03T17:46:46Z

← Older revision		Revision as of 12:46, 3 July 2025
Line 26:		Line 26:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 22:07, 25 May 2025

2025-05-25T22:07:07Z

← Older revision		Revision as of 17:07, 25 May 2025
Line 91:		Line 91:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|
Line 110:		Line 110:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|
Line 127:		Line 127:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|''MED12''		\|''MED12''

Bailey.Glen at 20:29, 25 May 2025

2025-05-25T20:29:25Z

← Older revision		Revision as of 15:29, 25 May 2025
Line 40:		Line 40:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Adenofibroma
	\|}		\|}

Kgeiersbach at 23:05, 1 May 2025

2025-05-01T23:05:37Z

← Older revision		Revision as of 18:05, 1 May 2025
Line 221:		Line 221:
	\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.		\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
	==Epigenomic Alterations==		==Epigenomic Alterations==
	~~Put your text here~~		<br />
	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==
	~~Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Please include references throughout the table. Do not delete the table.)''~~</~~span~~>		<br />
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 233:		Line 233:
	\|}		\|}
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==
	<br />		Next generation sequencing, PCR based testing with Sanger sequencing.<br />
	==Familial Forms==		==Familial Forms==
	<br />		Women with Carney complex due to an inherited pathogenic variant in PRKAR1A can develop myxoid fibroadenomas, which appear genetically distinct from conventional fibroadenomas.<ref>{{Cite journal\|last=Carney\|first=J. A.\|last2=Toorkey\|first2=B. C.\|date=1991-08\|title=Myxoid fibroadenoma and allied conditions (myxomatosis) of the breast. A heritable disorder with special associations including cardiac and cutaneous myxomas\|url=https://pubmed.ncbi.nlm.nih.gov/2069209\|journal=The American Journal of Surgical Pathology\|volume=15\|issue=8\|pages=713–721\|doi=10.1097/00000478-199108000-00001\|issn=0147-5185\|pmid=2069209}}</ref><ref>{{Cite journal\|last=Lozada\|first=John R.\|last2=Burke\|first2=Kathleen A.\|last3=Maguire\|first3=Aoife\|last4=Pareja\|first4=Fresia\|last5=Lim\|first5=Raymond S.\|last6=Kim\|first6=Jisun\|last7=Gularte-Merida\|first7=Rodrigo\|last8=Murray\|first8=Melissa P.\|last9=Brogi\|first9=Edi\|date=2017-10\|title=Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study\|url=https://pubmed.ncbi.nlm.nih.gov/28513873\|journal=Histopathology\|volume=71\|issue=4\|pages=626–634\|doi=10.1111/his.13258\|issn=1365-2559\|pmc=5597459\|pmid=28513873}}</ref> Beckwith-Wiedemann syndrome has been associated with the development of fibroadenomas in young patients.<ref>{{Cite journal\|last=Poh\|first=Melissa M.\|last2=Ballard\|first2=Tiffany N.\|last3=Wendel\|first3=J. Jason\|date=2010-06\|title=Beckwith-Wiedemann syndrome and juvenile fibroadenoma: a case report\|url=https://pubmed.ncbi.nlm.nih.gov/20506580\|journal=Annals of Plastic Surgery\|volume=64\|issue=6\|pages=803–806\|doi=10.1097/sap.0b013e3181b025f6\|issn=1536-3708\|pmid=20506580}}</ref><ref>{{Cite journal\|last=Raine\|first=P. A.\|last2=Noblett\|first2=H. R.\|last3=Houghton-Allen\|first3=B. W.\|last4=Campbell\|first4=P. E.\|date=1979-04\|title=Breast fibroadenoma and cardiac anomaly associated with EMG (Beckwith-Wiedemann) syndrome\|url=https://pubmed.ncbi.nlm.nih.gov/430311\|journal=The Journal of Pediatrics\|volume=94\|issue=4\|pages=633–634\|doi=10.1016/s0022-3476(79)80039-6\|issn=0022-3476\|pmid=430311}}</ref><br />
	==Additional Information==		==Additional Information==
	<br />		<br />
Line 250:		Line 250:
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases F]]		[[Category:Diseases F]]
			<references />

Kgeiersbach: updated content

2025-05-01T22:52:14Z

updated content

Show changes

Bailey.Glen at 18:11, 24 March 2025

2025-03-24T18:11:14Z

← Older revision		Revision as of 13:11, 24 March 2025
Line 1:		Line 1:
			{{DISPLAYTITLE:Fibroadenoma}}
			[[BRST5:Table_of_Contents\|Breast Tumours (WHO Classification, 5th ed.)]]

			{{Under Construction}}

	<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>		<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>
	==Primary Author(s)*==		==Primary Author(s)*==
	Put your text here<span style="color:#0070C0"> (''<span class="blue-text">EXAMPLE:</span>'' Jane Smith, PhD) </span>		Put your text here<span style="color:#0070C0"> (''<span class="blue-text">EXAMPLE:</span>'' Jane Smith, PhD) </span>
	==WHO Classification of Disease==		==WHO Classification of Disease==
	~~<span style="color:#0070C0">(''Instructions: This table’s content from the WHO book will be <u>autocompleted</u>.'')</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	!Structure		!Structure
Line 9:		Line 14:
	\|-		\|-
	\|Book		\|Book
	\|		\|Breast Tumours (5th ed.)
	\|-		\|-
	\|Category		\|Category
	\|		\|Fibroepithelial tumours and hamartomas of the breast
	\|-		\|-
	\|Family		\|Family
	\|		\|Fibroepithelial tumours and hamartomas of the breast: Introduction
	\|-		\|-
	\|Type		\|Type
	\|		\|Fibroadenoma
	\|-		\|-
	\|Subtype(s)		\|Subtype(s)
	\|		\|N/A
	\|}		\|}

	==WHO Essential and Desirable Genetic Diagnostic Criteria==		==WHO Essential and Desirable Genetic Diagnostic Criteria==
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>		<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
Line 278:		Line 284:
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

	Prior Author(s):		Prior Author(s):
			<nowiki>*</nowiki>''Citation of this Page'': “Fibroadenoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/BRST5:Fibroadenoma</nowiki>.
			[[Category:BRST5]][[Category:DISEASE]][[Category:Diseases F]]

Jennelleh at 20:06, 18 December 2024

2024-12-18T20:06:25Z

Show changes

Jennelleh: Jennelleh moved page Fibroadenoma to BRST5:Fibroadenoma without leaving a redirect: Moved to GTS5 version

2024-02-29T18:26:55Z

Jennelleh moved page Fibroadenoma to BRST5:Fibroadenoma without leaving a redirect: Moved to GTS5 version

← Older revision	Revision as of 13:26, 29 February 2024
(No difference)

Jennelleh at 21:18, 28 November 2023

2023-11-28T21:18:16Z

← Older revision		Revision as of 16:18, 28 November 2023
Line 1:		Line 1:
			<span style="color:#0070C0">(''General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])''</span>

	==Primary Author(s)*==		==Primary Author(s)*==

	Put your text here		Put your text here<span style="color:#0070C0"> (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics) </span>

	__TOC__		__TOC__

	==Cancer Category/Type==		==Cancer Category / Type==

	Put your text here		Put your text here
Line 11:		Line 13:
	==Cancer Sub-Classification / Subtype==		==Cancer Sub-Classification / Subtype==

	Put your text here		Put your text here

	==Definition / Description of Disease==		==Definition / Description of Disease==

	Put your text here		Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'') </span>

	==Synonyms / Terminology==		==Synonyms / Terminology==

	Put your text here		Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>

	==Epidemiology / Prevalence==		==Epidemiology / Prevalence==
Line 27:		Line 29:
	==Clinical Features==		==Clinical Features==

	Put your text here and fill in the table		Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Signs and Symptoms'''		\|'''Signs and Symptoms'''
Line 46:		Line 48:
	==Sites of Involvement==		==Sites of Involvement==

	Put your text here		Put your text here <span style="color:#0070C0">(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'') </span>

	==Morphologic Features==		==Morphologic Features==
Line 54:		Line 56:
	==Immunophenotype==		==Immunophenotype==

	Put your text here and fill in the table		Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 91:		Line 93:
	\|}		\|}

	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain / Loss / LOH==

	Put your text here and fill in the table		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 139:		Line 141:
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==

	Put your text here		Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 159:		Line 161:
	See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).		See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
	\|}		\|}
	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV / INDEL)==

	Put your text here and fill in the table		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 198:		Line 200:
	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==

	Put your text here and fill in the table		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 221:		Line 223:
	==Familial Forms==		==Familial Forms==

	Put your text here		Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>

	==Additional Information==		==Additional Information==
Line 229:		Line 231:
	==Links==		==Links==

	Put your text placeholder here (use "Link" icon at top of page)		Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page <span style="color:#0070C0">(''Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "<nowiki>http://www</nowiki>." portion.'')</span>

	==References==		==References==
	~~<references />~~		(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
	(use "Cite" icon at top of page)

	'''EXAMPLE Book'''		'''EXAMPLE Book'''